INTRODUCTION
============

Numerous examples of weak ABO subgroup phenotypes, such as A~2~, A~3~, A~m~, A~x~, A~y~, A~el~, B~3~, B~x~, B~m~, B~el~, B(A), and *cis*-AB, have been reported to date \[[@B1][@B2][@B3][@B4]\]. These phenotypes and their allelic frequencies vary according to geographic and ethnic background \[[@B1][@B2][@B3][@B4]\]. Among them, the *cis*-AB blood group is rare globally, yet it is relatively common in the Korean, Japanese, and Chinese populations \[[@B3][@B5][@B6]\]. Cho et al. \[[@B5]\] reported that the overall frequency of the *cis*-AB blood group in Koreans is 0.0354% (60/169,605), while in Japanese and Chinese blood donors, frequencies of 0.0012% \[[@B6]\] and 0.00066%, respectively, have been reported \[[@B7]\]. Interestingly, 26.4% (60/227) of ABO weak subgroups in Korea arise from the *cis-AB01* allele \[[@B5]\]. Although new alleles are continuously being reported, *cis-AB01* is the most prevalent allele in Korea \[[@B5]\].

The *cis*-AB blood group has attracted attention in transfusion medicine because of the interesting phenomenon that a single allele encodes both A and B antigens, as opposed to the regular *trans*-AB genotype \[[@B6][@B8]\]. Therefore, it can be difficult to correctly match ABO group for transfusion for the *cis*-AB subgroup, and paternity disputes can arise because of the unusual inheritance pattern, which can result in, for example, the birth of an O child from an AB mother.

The *cis*-AB subgroup still stands as a challenge to the novice eye in the clinical blood bank. This review provides an overview of the serological characteristics, genetic basis and inheritance, laboratory investigation, and clinical importance of the *cis*-AB blood group.

SEROLOGICAL CHARACTERISTICS OF THE *CIS*-AB BLOOD GROUP
=======================================================

There exist various phenotypes of the *cis*-AB blood group globally, and these phenotypes are associated with various *cis-AB* alleles ([Table 1](#T1){ref-type="table"}). Among them, *cis-AB01* is the most common allele. Yoshida et al. \[[@B9][@B10][@B11]\] first characterized a transferase enzyme with bifunctional activity (both A and B transferase activities) in the sera of individuals with the *cis-AB01* allele. The *cis-AB01* allele causes the A~2~B~3~ phenotype when co-inherited with the *O* allele, and more than seven different phenotypes when paired with *A* or *B* alleles have been reported \[[@B5]\].

Yamaguchi \[[@B6]\] reported three phenotypes of the *cis*-AB blood group in the Japanese population: A~2~B~3~, A~2~B, and A~1~B~3~, which are derived from the *cis-AB01/O*, *cis-AB01/B*, and *cis-AB01/A* genotypes, respectively. In large-scale blood donor studies, Cho et al. \[[@B5][@B12]\] reported that most Korean *cis*-AB donors exhibit not only the above three typical phenotypes but also a variety of other phenotypes ranging from A~1~B~x~, A~1~B~el~, A~int~B~3~, and A~int~B to typical A. These different phenotypes from a single *cis-AB01* allele are presumably due to allele competition (i.e., *cis-AB01/A*); the *cis*-AB mutant enzyme might not be able to produce its usual number of antigens due to competition for H-antigen with the co-inherited normal A transferase enzyme \[[@B5][@B13][@B14]\]. Four Korean cases with typical A phenotype without detectable B antigen expression on red blood cells (RBCs) in individuals with *cis-AB01/A* have been reported \[[@B12][@B15][@B16][@B17]\]. Without careful family studies, these cases would have been typed as typical A. Phenotypes, frequencies, serological characteristics, and genotypes of *cis*-AB blood groups reported in Korea are summarized in [Table 2](#T2){ref-type="table"}.

GENETIC BASIS AND INHERITANCE OF THE *CIS*-AB BLOOD GROUP
=========================================================

Among reported *cis-AB* alleles, some *cis-AB* alleles (*cis-AB01*, *cis-AB01var*, and *cis-AB02* to *cis-AB09*) are registered in the Blood Group Antigen Gene Mutation Database \[[@B1][@B18]\]. *cis-AB01*, *04*, and *08* have an A allele background, whereas *cis-AB02*, *cis-AB03*, *cis-AB05* to *cis-AB07*, and *cis-AB09* have a B allele background. Yamamoto et al. \[[@B19]\] first identified structural changes in the *cis-AB01* allele, using the *A102* allele as a reference. The coding sequence of the *cis-AB01* allele is identical to that of the *A102* allele except for Gly268Ala (c.803G\>C) in exon 7, whereas the *cis-AB02* allele sequence is identical to that of the *B102* allele except for Leu266Met (c.796A\>C) (GenBank accession No. AF062487). The most recently discovered *cis*-AB09 arises from a *de novo* c.796A\>G nucleotide substitution in the *ABO\*B101* allele \[[@B20]\]. The classification of *cis*-AB alleles according to the allele backbone, along with nucleotide and amino acid changes and reported phenotypes, is presented in [Table 1](#T1){ref-type="table"}.

The inheritance pattern of the *cis*-AB blood group appears to violate the typical Mendelian inheritance pattern. The *cis*-AB phenotype raises questions about an apparently paradoxical inheritance of the ABO blood group, such as cases of birth of an O or AB child from an AB father and O mother \[[@B21][@B22]\]. However, in such cases, the AB type in the family is not a typical AB type, but rather the *cis*-A~2~B~3~ blood group in which the A and B characteristics are inherited from one parent. Therefore, the inheritance pattern looks paradoxical, whereas in fact, it exactly follows the general Mendelian inheritance of ABO blood groups. Based on analysis of some unexplained *cis*-AB cases, Yamaguchi et al. \[[@B6][@B23]\] observed inheritance to follow a *cis*-regulated pattern, in contrast to regular *trans*-AB, and first coined the term *cis*-AB blood group. Representative Korean family trees illustrating the inheritance pattern are shown in [Fig. 1](#F1){ref-type="fig"}. Among the several *cis*-AB alleles, *cis-AB09* is of particular interest, as it was reported as a *de novo* mutation (c.796A\>G) in a Korean family, in which both the father and mother had blood group B \[[@B20]\].

It is of sociological interest that, in contrast to Western culture, individuals in Korea and Japan generally know their ABO blood type. In Korea, it is possible to know one\'s ABO/RhD blood types from routine testing during regular health check-ups at school age (or for men, during military service). In this context, the *cis*-AB type can potentially lead to paternity issues (e.g., when an individual has O or AB \[actually *cis*-AB\] blood type and the father and mother are known to be O and AB \[actually *cis*-AB\], respectively). Further, this implies that cases of *cis*-AB can be detected in routine ABO typing of a newborn cord blood samples.

LABORATORY INVESTIGATION OF THE *CIS*-AB BLOOD GROUP
====================================================

Owing to its serological characteristic, the *cis*-AB01 blood group is often encountered in pre-transfusion or donor screening. Samples from *cis*-AB01 subjects present forward or reverse ABO blood typing as ABO discrepancy; it may be commonly suspected when there is weak agglutination of RBCs with anti-B reagent in cell typing and weak agglutination with B cells in serum typing. Weak agglutination with B cells can be enhanced when the reaction is incubated at room temperature for 15 minutes. In contrast to *cis*-A~1~B~3~, the *trans*-A~1~B~3~ blood group originated from heterozygosity of A~1~ and B~3~ shows no agglutination with B cells in serum typing, despite prolonged incubation. In addition, a measurable amount of H antigen is suggestive of the *cis-AB01* blood group \[[@B22]\].

The representative A~2~B~3~ phenotype can be detected by skilled laboratory personnel through several serological methods, such as plate and tube methods. Not all medical technologists can be expected to reach this level of expertise, and one study reported serious consequences after *cis*-AB was identified as typical A \[[@B24]\]. After the introduction of automated ABO grouping devices, one research group encountered multiple cases of misidentification of *cis*-AB samples as typical AB when using a device that applies the microplate method \[[@B25]\]. In addition to the confirmation of typical A~2~B~3~ phenotypes as *cis*-AB, other phenotypes of *cis*-AB blood are often missed during routine serological testing, and ABO genotyping is the sole method for confirmation. For example, a case of A~int~B phenotype with anti-A antibodies could not be initially suspected of *cis*-AB type, but was confirmed by ABO genotyping \[[@B26]\].

After the introduction of ABO genotyping in clinical blood banks, it has become a valuable tool complementary to serology for correctly determining the ABO blood groups of both patients and donors \[[@B2][@B27]\]. Before the broad use of ABO gene testing, the *cis*-AB blood group was confirmed by serological investigations together with family study. However, family study is often impossible, and the introduction of ABO genotyping has thus resolved many issues in this regard \[[@B22]\].

Various genotyping methods can be employed to confirm *cis*-AB in cases of ABO discrepancy. Allele-specific (AS-)PCR, PCR-restriction fragment length polymorphism (RFLP), and/or direct sequencing of exons 6 and 7 of the *ABO* gene have been used for clinical purposes \[[@B27][@B28][@B29]\]. However, sequencing of the full coding region (exons 1--7), including regulatory regions of the gene, and cloning/allele-separation are necessary for research purposes (i.e., discovery of a novel *cis-AB* allele) \[[@B20][@B30]\]. Next-generation sequencing has been applied to blood group genes, and it will also be useful for *ABO* subgroup genes, including *cis-AB* alleles \[[@B31]\]. The *cis*-AB blood group can be detected by several methods ([Table 3](#T3){ref-type="table"}).

CLINICAL IMPORTANCE OF THE *CIS*-AB BLOOD GROUP IN TRANSFUSION PRACTICE
=======================================================================

Various approaches for transfusion for *cis*-AB patients are available. One is autologous blood transfusion, including preoperative autologous deposit \[[@B32]\], intraoperative salvage, and postoperative salvage \[[@B33][@B34]\]. However, preoperative autologous deposit can be applied in few cases, such as when intraoperative bleeding is predicted and the patient\'s preoperative condition is good \[[@B32]\]. In another approach, blood from a family member having the same blood type can be used for transfusion after irradiation to prevent transfusion-associated graft-versus-host disease. Oh et al. \[[@B34]\] reported safe transfusion of type O RBCs to *cis*-AB without adverse transfusion reaction. According to the Blood Transfusion Guideline 4th edition, in Korea, O RBCs (or A RBCs when anti-A is not detectable in the serum) and type AB plasma or platelets are recommended for patients with the *cis*-AB blood group \[[@B35]\].

Although most *cis*-AB subgroups can be accurately typed in the hospital blood bank, some cases may be misinterpreted as AB or A type \[[@B25][@B26]\]. In a case of *cis*-A~1~B~3~ interpreted as typical A, transfusion of four units of type A RBCs and four units of type A fresh frozen plasma (FFP) caused delayed transfusion adverse effects, because the results of pre-transfusion cross-match had not been properly interpreted \[[@B24]\]. Although reaction between the B antigen of the cis-AB patient and anti-B antibodies from the A type FFP is theoretically possible, the authors could not draw a definitive conclusion on the cause of hemolysis \[[@B24]\].

Another group reported a case of transfusion of type A RBCs, FFP, and platelets to a 14-year-old boy with *cis*-A~2~B~3~ blood type. Reverse typing showed that his serum contained anti-B but no anti-A antibodies. The patient did not show adverse reactions, which can be explained by the weak B antigen on his RBCs without anti-A antibodies against the transfused A RBCs. The same patient had been transfused with typical AB blood at the age of 13 months without any adverse reaction, which can also be explained by the fact that he may have had no or low anti-A and anti-B antibodies in his serum against the transfused AB blood during this first transfusion \[[@B36]\].

*Cis*-AB is difficult to determine, as it presents as more than one phenotype. The various phenotypes make quick blood group determination difficult. Therefore, universal blood (O-type RBCs and AB-type FFP/platelets) is recommended, as it can be safely used for patients with the cis-AB blood group.
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###### Classification, *cis*-AB alleles, nucleotide and amino acid changes, and phenotypes of *cis*-AB blood groups reported in the literature

![](alm-39-115-i001)

  Backbone        Allele                                                                                   Nucleotide^\*^ changes                                  Amino acid^\*^ changes                        Phenotypes          GenBank accession No. (when available)   Reference
  --------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------- --------------------------------------------- ------------------- ---------------------------------------- ---------------------------------------------
  A backbone      *cis-AB01*                                                                               467C \> T; 803G \> C                                    P156L; G268A                                  A~2~B~3~            [AF134427-4428]{.ul}                     Cho et al. \[[@B5]\]; Cho et al. \[[@B12]\]
  *cis-AB01var*   803G \> C; 1,009A \> G                                                                   G268A; R337G                                            AxBx                                          [JQ824867]{.ul}     Cai et al. \[[@B3]\]                     
  *cis-AB04*      467C \> T; 796C \> A                                                                     P156L; L266M                                            A~2~B                                         Not submitted       Yoon et al. \[[@B37]\]                   
  *cis-AB08*      467C \> T; 724G \> T; 803G \> C                                                          P156L; E242X; G268A                                     NA                                            [JF304777]{.ul}     Liu et al. \[[@B38]\]                    
  *cis-AB new*    467C \> T; 803G \> C; 930G \> A; 1,096G \> A                                             P156L; G268A                                            A~2~B~3~                                      [KR870035]{.ul}     Not published                            
  B backbone      *cis-AB02*                                                                               297A \> G; 526C \> G; 657C \> T; 703G \> A; 803G \> C   R176G; G235S; G268A                           A~2~B, A~int~B~x~   [AF062487]{.ul}                          Mifsud et al. \[[@B39]\]
  *cis-AB03*      297A \> G; 526C \> G; 657C \> T; 700C \> T; 703G \> A; 796C \> A; 803G \> C; 930G \> A   R176G; P234S; G235S; L266M; G268A;                      A~2~B                                         AF408431            [Roubinet]{.ul} et al. \[[@B40]\]        
  *cis-AB05*      297A \> G; 526C \> G; 657C \> T; 703G \> A; 796C \> A; 930G \> A                         R176G; G235S; L266M                                     A~2~B                                         Not submitted       Deng et al. \[[@B41]\]                   
  *cis-AB06*      297A \> G; 657C \> T; 703G \> A; 796C \> A; 803G \> C; 930G \> A                         G235S; L266M; G268A                                     A~2~B                                         [FJ851690]{.ul}     Zhu et al. \[[@B42]\]                    
  *cis-AB07*      297A \> G; 526C \> G; 657C \> T; 703G \> A; 796C \> A; 797T \> C; 803G \> C; 930G \> A   R176G; G235S; L266M; G268A                              A~2~B~w~                                      [JX473237]{.ul}     Mifsud et al. \[[@B39]\]                 
  cis-AB09^†^     297A \> G; 526C \> G; 657C \> T; 703G \> A; 796C \> G‡; 803G \> C; 930G \> A             T99T; R176G; H219H; G235S; L266V; L310L                 A~2~B with 1+ agglutination with A~1~ cells   [KJ766004]{.ul}     Lee et al. \[[@B20]\]                    

^\*^Changes in nucleotides and amino acids in the *cis-AB01* allele are described according to the *A101* allele; ^†^The *cis*-AB09 allele arises from a *de novo* nucleotide substitution c.796A\>G (p.M266V) in the B glycosyltransferase gene; ^‡^The c.796C\>G on the *A101* allele background is the same as c.796A\>G on the *B101* allele background.

Abbreviation: NA, not applicable.

###### Phenotypes, frequencies, serological characteristics, and genotypes of the *cis*-AB01 blood group reported in Korea

![](alm-39-115-i002)

  Phenotype      Frequency (%)   Cell type   Serum type   Genotypes   Reference                                                          
  -------------- --------------- ----------- ------------ ----------- ----------- ---------- ---------- ---------- --------------------- ------------------------------------------------------------------------------------------------
  A~2~B~3~       60              4+          1+ \~ 3+     −           4+          3+ \~ 4+   \- \~ 2+   1+ \~ 2+   cis-AB01/O01 or O02   Cho et al. \[[@B5]\]; Cho et al. \[[@B12]\]; Whang et al. \[[@B15]\]; Chun et al. \[[@B25]\]
  A~1~B~3~       15.0            4+          1+ \~ 3+     3+ \~ 4+    NA          NA         −          1+ \~ 2+   *cis-AB01/A102*       Cho et al. \[[@B5]\]; Chun et al. \[[@B25]\]
  A~2~B          15.0            4+          4+           −           4+          −          \- \~ 2+   −          *cis-AB01/B101*       Cho et al.\[[@B5]\]; Cho et al. \[[@B12]\]; Cho et al. \[[@B22]\]
  A~1~B~w~^\*^   6.7             4+          trace        4+          NA          NA         −          1+ \~ 2+   *cis-AB01/A102*       Cho et al. \[[@B5]\]; Chun et al. \[[@B25]\]
  A~int~B~3~     3.3             4+          1+ \~ 3+     1+          NA          NA         −          1+ \~ 2+   *cis-AB01/A102*       Cho et al. \[[@B5]\];
  A~int~B        Rare            4+          4+           1+          4+          NA         trace      −          *cis-AB01/B101*       Chun et al. \[[@B25]\]; Park et al. \[[@B26]\]
  A~1~           Rare            4+          −            4+          4+          −          −          3+         *cis-AB01/A102*       Cho et al. \[[@B12]\]; Whang et al. \[[@B15]\]; Kang et al. \[[@B16]\]; Song et al. \[[@B17]\]

^\*^A~1~B~el~, A~1~B~x~, A~1~B~m~.

Abbreviation: NA, not applicable.

###### Serological and molecular tests for detection of the *cis*-AB blood group

![](alm-39-115-i003)

  Method                                                                                                                     Remark                                                                                                                         Reference                                                  
  -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------- -----------------------------------------------
  Serology (*cis*-A~2~B~3~)                                                                                                  Plate (tile)                                                                                                                   \- Weak or delayed red cell reactivity to anti-B reagent   Chun et al. \[[@B25]\]; Kim et al. \[[@B34]\]
  Tube                                                                                                                       \- Weak red cell reactivity to anti-B reagent (mixed field agglutination)                                                      Chun et al. \[[@B25]\]                                     
  \- Weak serum reactivity to B cells can be enhanced by incubation at room temperature for 15 minutes                                                                                                                                                                                                                 
  Microcolumn                                                                                                                \- Medium-sized clumps of agglutinated cells in the upper half of the gel column, can be observed in cell typing (to anti-B)   Unpublished data                                           
  Automated microplate                                                                                                       \- Misidentification of cis-A2B3 samples as typical AB can be possible                                                         Chun et al. \[[@B25]\]                                     
  Molecular                                                                                                                  AS-PCR/ PCR-RFLP                                                                                                               \- Can be only used for known cis-AB alleles               Fukumori et al. \[[@B29]\]
  Sequencing                                                                                                                 \- For clinical purpose, sequencing of ABO gene exons \[[@B6][@B7]\] are commonly used                                         Won et al. \[[@B28]\]; Won et al. \[[@B30]\]               
  \- For research purpose, sequencing of the all of ABO gene coding region (exons \[1--7\]) and regulatory regions is used                                                                                                                                                                                             
  Cloning/allele-separation and sequencing                                                                                   \- Required for novel cis-AB allele study                                                                                      Lee et al. \[[@B20]\]                                      
  Next-generation sequencing                                                                                                 \- Required for novel cis-AB allele study                                                                                      Moller et al. \[[@B31]\]                                   

Abbreviations: AS-PCR, allele specific-PCR; PCR-RFLP, PCR-restriction fragment length polymorphism.
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